NewEdge Advisors LLC Acquires 5,958 Shares of Sanofi (NASDAQ:SNY)

NewEdge Advisors LLC boosted its holdings in Sanofi (NASDAQ:SNY - Free Report) by 19.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 36,796 shares of the company's stock after purchasing an additional 5,958 shares during the quarter. NewEdge Advisors LLC's holdings in Sanofi were worth $1,775,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Synergy Asset Management LLC acquired a new stake in Sanofi in the 4th quarter worth about $25,000. McClarren Financial Advisors Inc. increased its holdings in Sanofi by 952.6% in the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock valued at $28,000 after buying an additional 543 shares during the period. Bessemer Group Inc. increased its holdings in Sanofi by 59.8% in the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company's stock valued at $32,000 after buying an additional 242 shares during the period. Lee Danner & Bass Inc. bought a new position in Sanofi in the 4th quarter valued at about $31,000. Finally, Sierra Ocean LLC bought a new position in Sanofi in the 4th quarter valued at about $44,000. Institutional investors and hedge funds own 14.04% of the company's stock.

Sanofi Trading Up 0.8 %

NASDAQ:SNY traded up $0.44 during trading hours on Monday, hitting $52.76. 2,005,642 shares of the company were exchanged, compared to its average volume of 2,363,903. The stock has a market capitalization of $133.29 billion, a price-to-earnings ratio of 21.19, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. Sanofi has a one year low of $45.80 and a one year high of $60.12. The company has a fifty day simple moving average of $54.51 and a 200 day simple moving average of $52.03.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its earnings results on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.04. The business had revenue of $10.41 billion during the quarter, compared to analyst estimates of $9.79 billion. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Sanofi's revenue for the quarter was down 11.0% compared to the same quarter last year. During the same period last year, the company earned $1.78 EPS. Sell-side analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which will be paid on Thursday, June 12th. Investors of record on Friday, May 9th will be given a dividend of $2.0369 per share. This is a positive change from Sanofi's previous annual dividend of $1.48. This represents a yield of 3.1%. The ex-dividend date is Friday, May 9th. Sanofi's dividend payout ratio (DPR) is currently 57.14%.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. The Goldman Sachs Group assumed coverage on shares of Sanofi in a report on Friday, March 21st. They issued a "neutral" rating and a $65.00 target price on the stock. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. Sanford C. Bernstein raised shares of Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. Finally, BNP Paribas assumed coverage on shares of Sanofi in a report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price target on the stock. Three analysts have rated the stock with a hold rating, two have given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $63.33.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.